Roivant Sciences (ROIV) Income towards Parent Company (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Income towards Parent Company came in at -$290.6 million in Q2 2026, down 6.1% on a YoY basis from -$309.5 million in Q2 2025, and up 61.44% quarter-over-quarter from -$753.7 million in Q4 2025.
Analysis
Roivant Sciences (ROIV) Income towards Parent Company (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Income towards Parent Company for 7 consecutive years, with -$290.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income towards Parent Company fell 6.1% year-over-year to -$290.6 million; the trailing twelve-month figure through Jun 2026 stood at -$1.5 billion (down 157.62% YoY), and the FY2026 full-year result was -$397.9 million, down 11.59% from the prior year.
- Income towards Parent Company grew to -$290.6 million in Q2 2026 per ROIV's latest filing, from -$753.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $4.9 billion in Q4 2023 and bottomed at -$1.1 billion in Q4 2022.
- Historically, Income towards Parent Company has averaged $56.1 million across 5 years, with a median of -$290.6 million in 2026.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company surged 564.5% in 2023, then slumped 844.63% in 2025.
- Over 5 years, Income towards Parent Company stood at -$1.1 billion in 2022, then soared by 564.5% to $4.9 billion in 2023, then slumped by 101.63% to -$79.8 million in 2024, then plunged by 844.63% to -$753.7 million in 2025, then jumped by 61.44% to -$290.6 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$290.6 million, -$753.7 million, and -$166.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.13 Bn | 198.14 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.95 Bn | 178.77 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.50 Bn | 124.65 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.67 Bn | 74.68 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.23 Bn | 30.92 Bn | 992.69 Mn |
| 8 | Biogen | 31.46 Bn | 30.18 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.19 Bn | 30.19 Bn | 1.16 Mn |
| 10 | Insmed | 27.89 Bn | 26.72 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -290.61 Mn |
| Dec 31, 2025 | -753.65 Mn |
| Sep 30, 2025 | -166.04 Mn |
| Jun 30, 2025 | -273.91 Mn |
| Dec 31, 2024 | -79.78 Mn |
| Sep 30, 2024 | -279.92 Mn |
| Jun 30, 2024 | 57.49 Mn |
| Dec 31, 2023 | 4.90 Bn |
| Sep 30, 2023 | -331.12 Mn |
| Jun 30, 2023 | -327.85 Mn |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -315.92 Mn |
| Jun 30, 2022 | -353.78 Mn |
| Dec 31, 2021 | -632.80 Mn |
| Sep 30, 2021 | -225.64 Mn |
| Jun 30, 2021 | -101.08 Mn |
| Dec 31, 2020 | -275.60 Mn |
| Sep 30, 2020 | -53.50 Mn |
| Jun 30, 2020 | -7.98 Mn |